Avalyn Pharma Inc AVLN

$AVLN Phase 2b trial fully enrolled\\

Jefferies🏁 $VCRE Buy; PT $25 and said -- VCRE is a high-risk/high-reward IPF play, but we think the setup into mid-2027 Ph2b ASPIRE data is favorable. $RHHBY $AVLN UTHR BMY Jefferies added—Precedent Ph2a AIR data is hard to interpret and almost too good to believe, but we think the synthetic-control analysis, biomarker trends, preclinical work, and MOA rationale all point the same way. Importantly, the bar for ASPIRE is lower than what we saw in AIR: efficacy in line with SOC + clean tolerability should be a win. Initiate BUY.

$AVLN Raymond James started coverage Friday with an Outperform and a 60 target, the seventh firm on a five-month-old IPO. Consensus sits at Moderate Buy with a 60 average target, more than double Friday's 28.13 close. The street is pricing this as de-risked: Avalyn isn't inventing molecules, it's reformulating the only two approved antifibrotics (Roche's Esbriet, BI's Ofev) as inhaled versions, aiming to put more drug in the lung and dodge the GI and photosensitivity side effects that keep patients off the pills. But the first hard data is a year out. Phase 2b MIST of AP01 (inhaled pirfenidone) randomized 398 progressive pulmonary fibrosis patients, with topline due H2 2027; AP02 (inhaled nintedanib) reads late 2027. September hinted at how the company is thinking about the next step: it added a former FDA pulmonary division director to the board. That's a Phase 3 prep hire, not a science hire. Cash supports the wait: 413.5M on hand funds operations into 2029.

Stifel y'day reitd $CTNM Buy-$28 after CTNM shrs traded⬇️on the circulation of a protocol amendment for $BMY's admilparant trial—the outcome of which is core to the CTNM thesis for PIPE-791. $AVLN AGMB PLRX VCRE GPCR ARWR UTHR LQDA Here's what Stifel said about the BMY Tx, re the liver safety issue and its readthrough to PIPE-791: https://x.com/Quantumup1/status/2105326314798383117?s=20

$AVLN Outstanding article that hits the mark on AVLN's current state. So if you want to refresh your AVLN insights or learn about AVLN from scratch, this is a must read. https://everyticker.com/quote/AVLN/analysis/avalyn-pharma-s-inhaled-gamble-can-lung-targeted-delivery-justify-a-1-6b-valuation-with-zero-revenue-nasdaq-avln

$AVLN reached the measured move price projection at the 50% retracement level with bullish divergences on the technical indicators

$MNKD $AVLN is up ~$4 after earnings release. Is in P2 for same drug as Mannkind, nintedanib but in the nebulized form. It's current market cap is ~$1.74 billion. The comparison is being posted to demonstrate ow the market sees one company vs another even with the same drug at the same stage being tested.

$AVLN looking good guys. We might be thr only ones that know about this monster. Which is nice 😆